المؤلفون: Theodoropoulou, Marily, Tichomirowa, Maria A, Sievers, Caroline, Yassouridis, Alexander, Arzberger, Thomas, Hougrand, Olivier, Deprez, Manuel, Daly, Adrian, Petrossians, Patrick, Pagotto, Uberto, Beckers, Albert, Stalla, Gunter K

المصدر: International Journal of Cancer, 125 (9), 2122-6 (2009-11)

مصطلحات موضوعية: Acromegaly/drug therapy, Adolescent, Adult, Aged, Cell Cycle Proteins/analysis, Cohort Studies, Female, Human Growth Hormone/blood, Humans, Insulin-Like Growth Factor I/analysis, Male, Middle Aged, Octreotide/therapeutic use, Peptides, Cyclic/therapeutic use, Pituitary Neoplasms/chemistry/drug therapy, Retrospective Studies, Somatostatin/analogs & derivatives/therapeutic use, Transcription Factors/analysis, Tumor Suppressor Proteins/analysis, Human health sciences, Endocrinology, metabolism & nutrition, Sciences de la santé humaine, Endocrinologie, métabolisme & nutrition

الوصف: Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting pituitary tumors. Although a good portion of acromegalic patients gets normalized after SSA treatment, strict hormonal control is not achieved in a sizeable proportion of these patients. The reasons for this incomplete response to SSA treatment are unclear. We have found that the tumor suppressor ZAC1 (LOT1/PLAGL1) is essential for the antiproliferative effect of SSA in pituitary tumor cells. The aim of the present retrospective cohort study was to determine whether ZAC1 immunoreactivity in archival somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with SSA before surgery, was associated with response to SSA (normalization of GH, IGF-I and presence of tumor shrinkage). All tumors displayed ZAC1 immunoreactivity [weak (+; n = 15), moderate (++; n = 16) and strong (+++; n = 14)]. A significant positive correlation was found between strong ZAC1 immunoreactivity and IGF-I normalization and presence of tumor shrinkage after SSA treatment, which was not affected by age at diagnosis, gender or duration of SSA treatment. These in vivo data combined with the antiproliferative properties of ZAC1/Zac1 provide evidence of a mechanistic role for this transcription factor on SSA induced tumor shrinkage and hormone normalization.

Relation: urn:issn:0020-7136; urn:issn:1097-0215

URL الوصول: https://orbi.uliege.be/handle/2268/59309

المؤلفون: Marcio Nucci, D Raghunadharao, Oliver A. Cornely, Luis Ostrosky-Zeichner, Sonja Koblinger, Antonio Freire, Andrew J. Ullmann, Amorn Leelarasamee, Johan Decruyenaere, Markus Ruhnke, Ploenchan Chetchotisakd, Heike Diekmann-Berndt, Ernst-Ruediger Kuse, V Ramasubramanian, Olivier Lortholary, Jagdev Singh Sekhon, Ignace Demeyer, Clovis Arns da Cunha, Didier Pittet, Carlos H. Barrios, Frédérique Jacobs

المصدر: The Lancet, Vol. 369, No 9572 (2007) pp. 1519-1527

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Antifungal Agents, Adolescent, Lipoproteins, Amphotericin B/ therapeutic use, Microbial Sensitivity Tests, Lipoproteins/ therapeutic use, Peptides, Cyclic, Echinocandins, Lipopeptides, chemistry.chemical_compound, Double-Blind Method, Amphotericin B, Internal medicine, Peptides, Cyclic/ therapeutic use, medicine, Humans, Adverse effect, Mycosis, Fungemia, Candidiasis/complications/ drug therapy/microbiology, APACHE, Aged, ddc:616, Aged, 80 and over, Voriconazole, business.industry, Antifungal Agents/ therapeutic use, Candidiasis, Micafungin, General Medicine, Middle Aged, bacterial infections and mycoses, medicine.disease, Apache, Surgery, Treatment Outcome, chemistry, Female, Caspofungin, business, Fluconazole, medicine.drug

الوصف: Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288. Findings 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89·6%) patients treated with micafungin and 170 (89·5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0·7% (95% CI −5·3 to 6·7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events—including those that were serious or led to treatment discontinuation—with micafungin than there were with liposomal amphotericin B. Interpretation Micafungin was as effective as—and caused fewer adverse events than—liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c612bb7c29ee2d0d7e7effdc384368
https://doi.org/10.1016/s0140-6736(07)60605-9

المؤلفون: Martin G. Täuber, Jorge Garbino, Michel P. Glauser, Jacques Bille, Oscar Marchetti, Ursula Flückiger, Alexander Imhof, Philippe Eggimann, Christian Ruef, Stefan Zimmerli, Didier Pittet, Thierry Calandra

المصدر: Swiss Medical Weekly, Vol. 136, No 29-30 (2006) pp. 447-463

مصطلحات موضوعية: Azoles, medicine.medical_specialty, Antifungal Agents, Combination therapy, Polyenes/therapeutic use, Salvage therapy, Polyenes, Candidiasis/ drug therapy/epidemiology, Aspergillosis, Peptides, Cyclic, Fungal Proteins, Echinocandins, chemistry.chemical_compound, Switzerland/epidemiology, Pharmacotherapy, Aspergillosis/ drug therapy/epidemiology, Fungal Proteins/therapeutic use, Peptides, Cyclic/therapeutic use, Amphotericin B deoxycholate, medicine, Humans, Intensive care medicine, ddc:616, Voriconazole, Clinical Trials as Topic, business.industry, Candidiasis, General Medicine, bacterial infections and mycoses, medicine.disease, chemistry, Drug Therapy, Combination, Azoles/therapeutic use, Antifungal Agents/adverse effects/ therapeutic use, Caspofungin, business, Switzerland, Fluconazole, medicine.drug

الوصف: A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6aaaf07836c8237f50a7dacff12a86
https://doi.org/10.4414/smw.2006.11392

المؤلفون: Flückiger, U., Marchetti, O., Bille, J., Eggimann, P., Zimmerli, S., Imhof, A., Garbino, J., Ruef, C., Pittet, D., Täuber, M., Glauser, M., Calandra, T.

المساهمون: Fungal Infection Network of Switzerland (FUNGINOS)

المصدر: Swiss medical weekly, vol. 136, no. 29-30, pp. 447-463

مصطلحات موضوعية: Antifungal Agents/adverse effects, Antifungal Agents/therapeutic use, Aspergillosis/drug therapy, Aspergillosis/epidemiology, Azoles/therapeutic use, Candidiasis/drug therapy, Candidiasis/epidemiology, Clinical Trials as Topic, Drug Therapy, Combination, Echinocandins, Fungal Proteins/therapeutic use, Humans, Peptides, Cyclic/therapeutic use, Polyenes/therapeutic use, Switzerland/epidemiology, bacterial infections and mycoses

الوصف: A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1900::4bf93a707028904738be31ac6d7156b9
https://serval.unil.ch/resource/serval:BIB_B671A5617F0E.P001/REF.pdf

المؤلفون: Daniel Pablo Lew, Pierre Hoffmeyer, Peter Rohner, Mathieu Assal, Louis Bernard, Laurence Legout

المصدر: Scandinavian Journal of Infectious Diseases, Vol. 38, No 8 (2006) pp. 728-730

مصطلحات موضوعية: Microbiology (medical), Male, medicine.medical_specialty, Arthritis, HIV Infections, HIV Infections/ microbiology, Candida parapsilosis, Peptides, Cyclic, Candidiasis/ drug therapy/microbiology/virology, chemistry.chemical_compound, Lipopeptides, Echinocandins, Caspofungin, Internal medicine, Peptides, Cyclic/ therapeutic use, medicine, Humans, ddc:576.5, Sida, Fluconazole, Candida, Candida/ isolation & purification, General Immunology and Microbiology, biology, Osteomyelitis, Candidiasis, HIV, Hiv, Drug Resistance, Microbial, General Medicine, Middle Aged, medicine.disease, biology.organism_classification, Osteomyelitis/ drug therapy/microbiology/virology, Infectious Diseases, chemistry, Fluconazole/ pharmacology, Immunology, Fluconazole resistant, Viral disease, medicine.drug

الوصف: Treating Candida arthritis is challenging. We report a case of Candida parapsilosis arthritis successfully treated with caspofungin. We illustrate the likelihood of severe infections due fluconazole resistant C. parapsilosis after extensive fluconazole use and discuss the role of newer antifungal agents in the treatment of arthritis due to Candida spp.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21666b0e794524317933cba549d3303
https://archive-ouverte.unige.ch/unige:9384

المؤلفون: Baltogiannis, G. G., Tsalikakis, D. G., Mitsi, A. C., Hatzistergos, K. E., Elaiopoulos, D., Fotiadis, D. I., Kyriakides, Z. S., Kolettis, T. M.

مصطلحات موضوعية: Action Potentials/drug effects, Arrhythmias, Cardiac/*drug therapy/etiology/physiopathology, Peptides, Cyclic/*therapeutic use, Rats, Receptor, Endothelin A/*antagonists & inhibitors, Telemetry/methods, Random Allocation, Tachycardia, Ventricular/drug therapy/physiopathology, Ventricular Fibrillation/drug therapy/physiopathology, Electrocardiography, Ambulatory, Myocardial Infarction/complications/*drug therapy/physiopathology, Animals, Female, Rats, Wistar

الوصف: OBJECTIVE: Endothelin-1 (ET-1) production increases during acute myocardial infarction (MI) and may contribute to the genesis of ventricular tachycardia (VT) and ventricular fibrillation (VF). However, the antiarrhythmic effects of ET-1 receptor blockade, examined shortly after MI, have been debated. In the present study, we examined the effects of such treatment on VT/VF during the first 24 h post-MI. METHODS: Thirty-five Wistar rats (223+/-22 g) were randomly allocated to either the ET-1 receptor-A (ETA) antagonist BQ-123 (0.4 mg/kg, BQ-123 group, n=17), or normal saline (control group, n=18) and were subjected to coronary artery ligation. A single-lead electrocardiogram was continuously recorded for 24 h post-MI, using an implanted telemetry system, and episodes of VT/VF were analyzed. Monophasic action potential (MAP) recordings were obtained from the left (LV) and right (RV) ventricular epicardium at baseline, 5 min after treatment and 24 h post-MI. RESULTS: There were 15.94+/-19.35 episodes/h/rat of VT/VF in the control group and 1.66+/-2.22 in the BQ-123 group (p=0.010), resulting in a lower (p=0.030) arrhythmic mortality in treated animals. The mean episode duration was 7.40+/-7.16 s for the control group and 2.30+/-1.37 s for the BQ-123 group (p=0.011). The maximum decrease in VT/VF was observed during the 1st, 5th and 6th hours post-MI. In the control group, LV MAP duration increased 24 h post-MI, displaying an increased beat-to-beat variation, but remained unchanged in the BQ-123 group. CONCLUSION: Acute ETA blockade reduces the incidence of VT/V F during the first 24-h post-MI in the rat, through a decrease in the dispersion of repolarization. Cardiovasc Res

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_____10561::ddd51f679f6fd476a6dc765fdd5cbb77
http://olympias.lib.uoi.gr/jspui/handle/123456789/21966

المؤلفون: Beckers, Albert, Betea, Daniela, Valdes Socin, Hernan Gonzalo, Stevenaert, Achille

المصدر: Journal of Internal Medicine, 253 (6), 599-605 (2003)

مصطلحات موضوعية: Acromegaly/drug therapy/radiotherapy/surgery, Adenoma/drug therapy/radiotherapy/surgery, Antineoplastic Agents, Hormonal/therapeutic use, Humans, Multiple Endocrine Neoplasia Type 1/drug therapy/radiotherapy/surgery, Octreotide/therapeutic use, Pancreatic Neoplasms/drug therapy/radiotherapy/surgery, Patient Selection, Peptides, Cyclic/therapeutic use, Prolactinoma/drug therapy/surgery, Somatostatin/analogs & derivatives/therapeutic use, Human health sciences, Endocrinology, metabolism & nutrition, Sciences de la santé humaine, Endocrinologie, métabolisme & nutrition

الوصف: The treatment of pituitary tumours strongly depends on their clinical presentation. In general, the treatment aims are reducing tumour volume and/or decreasing hormone hypersecretion. It relies on single or a combination of three different methods: surgery, medication and radiotherapy. The rationale for deciding the treatment are many but include the aggressiveness of the tumour. The aetiologies of sporadic pituitary adenomas are not fully understood. However, several causes have been identified resulting in specific familial phenotypes like multiple endocrine neoplasia type I (MEN1). MEN1 is related to mutations in the MEN1 gene, a tumour suppressor gene localized on chromosome 11q13 and which encodes menin, a 610 amino acid protein. During the last years, an evidence progressively emerged that MEN1-related adenomas were more aggressive and less responsive to therapy than their sporadic counterparts. In this article, we review the differences between sporadic and MEN1-related adenomas and suggest specific ways of treatment and follow-up for MEN1-related tumours.

Relation: urn:issn:0954-6820; urn:issn:1365-2796

URL الوصول: https://orbi.uliege.be/handle/2268/15479

المصدر: Hepatology, 55 (3

مستخلص: Tegobuvir (GS-9190), a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS-9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1. The antiviral activity of tegobuvir and GS-9256 as oral combination therapy, or together with ribavirin (RBV) or pegylated interferon (Peg-IFN) alpha-2a and RBV, was assessed in a phase II, randomized, open-label trial. Treatment-naïve patients with genotype 1 HCV were assigned 28 days of tegobuvir 40 mg twice-daily (BID) and GS-9256 75 mg BID (n = 16), tegobuvir and GS-9256 plus RBV 1,000-1,200 mg daily (n = 15), or tegobuvir and GS-9256 plus Peg-IFN alpha-2a (180 μg once-weekly)/RBV (n = 15). The primary efficacy endpoint was rapid virologic response (RVR), with HCV RNA <25 IU/mL at day 28. After 28 days, all patients received Peg-IFN/RBV. All patients with viral rebound or nonresponse, defined as >0.5-log(10) increase in HCV RNA from nadir or <2-log decrease at day 5, initiated Peg-IFN/RBV immediately. Median maximal reductions in HCV RNA were -4.1 log(10) IU/mL for tegobuvir/GS-9256, -5.1 log(10) IU/mL for tegobuvir/GS-9256/RBV, and -5.7 log(10) IU/mL for tegobuvir/9256/Peg-IFN/RBV. RVR was observed in 7% (1 of 15) of patients receiving tegobuvir/GS-9256, 38% (5 of 13) receiving tegobuvir/GS-9256/RBV, and 100% (14 of 14) receiving tegobuvir/9256/PEG-IFN/RBV. The addition of Peg-IFN/RBV at day 28 or earlier resulted in HCV RNA <25 IU/mL at week 24 in 67% (10 of 15), 100% (13 of 13), and 94% (13 of 14) of patients in the three treatment groups. Transient elevations in serum bilirubin occurred in all treatment groups.
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
FLWIN
info:eu-repo/semantics/published

مصطلحات الفهرس: Sciences bio-médicales et agricoles, Adult, Antiviral Agents -- therapeutic use, Dose-Response Relationship, Drug, Drug Therapy, Combination, Enzyme Inhibitors -- therapeutic use, Female, Genotype, Hepacivirus -- genetics, Hepatitis C -- blood -- drug therapy, Humans, Interferon-alpha -- therapeutic use, Male, Middle Aged, Peptides, Cyclic -- therapeutic use, Phosphinic Acids -- therapeutic use, Polyethylene Glycols -- therapeutic use, Protease Inhibitors -- therapeutic use, Purines -- therapeutic use, Pyridazines -- therapeutic use, RNA, Viral -- blood, Recombinant Proteins -- therapeutic use, Ribavirin -- therapeutic use, Treatment Outcome, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article

URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/156143
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL

مستخلص: Endocrine tumours of the gastrointestinal tract and pancreas may present at different disease stages with either hormonal or hormone-related symptoms/syndromes, or without hormonal symptoms. They may occur either sporadically or as part of hereditary syndromes. In the therapeutic approach to a patient with these tumours, excessive hormonal secretion and/or its effects should always be controlled first. Tumour-related deficiencies or disorders should also be corrected. Subsequently, control should be aimed at the tumour growth. Surgery is generally considered as first-line therapy for patients with localized disease, as it can be curative. However, in patients with metastatic disease the role of first-line surgery is not clearly established and other therapies should be considered, such as non-surgical cytoreductive therapies, biotherapy (with somatostatin analogues or interferon-alpha), embolization and chemoembolization of liver metastases, chemotherapy (with single or multiple dose regimens) and peptide receptor-targeted radiotherapy. The delicate balance of the use of the different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and pancreas emphasizes the importance of team approach and team expertise.

مصطلحات الفهرس: Gastrinoma/radiotherapy, Gastrointestinal Neoplasms/genetics/*therapy, Humans, Neuroendocrine Tumors/genetics/*therapy, Pancreatic Neoplasms/genetics/*therapy, Peptides, Cyclic/therapeutic use, info:eu-repo/semantics/article

URL: http://repub.eur.nl/pub/10323